{
  "label": "clinical_signal_03_ep_027",
  "artifact_type": "signal_episode",
  "artifact_id": "sha256:7080170cd3ea8be07970dade42c8e1392a80937ea0a01463fd8ace0530bcd49a",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:161174e8025b5c956602ccc4e17b4e677c58230b1b64641f357c400c448b8151"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:55:39.440625",
  "content": "## 2024-09-02 Daily Operations Summary\n\n### Enrollment\n- Total Randomized: 218\n- Active: 202\n- Screen Failures Cumulative: 68\n- Withdrawals Cumulative: 16\n\n#### Sites\n- Site 01 Enrolled: 22\n- Site 01 Active: 21\n- Site 01 Statin Concomitant: 6\n- Site 02 Enrolled: 16\n- Site 02 Active: 15\n- Site 02 Statin Concomitant: 4\n- Site 03 Enrolled: 20\n- Site 03 Active: 19\n- Site 03 Statin Concomitant: 5\n- Site 04 Enrolled: 14\n- Site 04 Active: 14\n- Site 04 Statin Concomitant: 3\n- Site 05 Enrolled: 18\n- Site 05 Active: 18\n- Site 05 Statin Concomitant: 5\n- Site 06 Enrolled: 13\n- Site 06 Active: 12\n- Site 06 Statin Concomitant: 4\n- Site 07 Enrolled: 24\n- Site 07 Active: 24\n- Site 07 Statin Concomitant: 7\n- Site 08 Enrolled: 16\n- Site 08 Active: 15\n- Site 08 Statin Concomitant: 4\n- Site 09 Enrolled: 18\n- Site 09 Active: 18\n- Site 09 Statin Concomitant: 5\n- Site 10 Enrolled: 14\n- Site 10 Active: 14\n- Site 10 Statin Concomitant: 4\n- Site 11 Enrolled: 20\n- Site 11 Active: 19\n- Site 11 Statin Concomitant: 6\n- Site 12 Enrolled: 16\n- Site 12 Active: 15\n- Site 12 Statin Concomitant: 5\n\n### Lab Panels\n#### Statin Subgroup\n- N: 53\n- ALT (U/L) Mean: 162.5\n- ALT (U/L) Median: 160.5\n- AST (U/L) Mean: 108.1\n- AST (U/L) Median: 106.5\n- Bilirubin (mg/dL) Mean: 2.44\n- Bilirubin (mg/dL) Median: 2.41\n- ALP (U/L) Mean: 69.2\n- ALP (U/L) Median: 55.0\n- Creatinine (mg/dL) Mean: 0.98\n- Creatinine (mg/dL) Median: 0.99\n- BUN (mg/dL) Mean: 17.4\n- BUN (mg/dL) Median: 15.0\n- WBC (K) Mean: 8.2\n- WBC (K) Median: 7.6\n- Platelets (K) Mean: 236\n- Platelets (K) Median: 223\n\n#### Non-Statin Subgroup\n- N: 129\n- ALT (U/L) Mean: 22.1\n- ALT (U/L) Median: 21.7\n- AST (U/L) Mean: 23.2\n- AST (U/L) Median: 21.7\n- Bilirubin (mg/dL) Mean: 0.63\n- Bilirubin (mg/dL) Median: 0.62\n- ALP (U/L) Mean: 52.7\n- ALP (U/L) Median: 53.7\n- Creatinine (mg/dL) Mean: 0.82\n- Creatinine (mg/dL) Median: 0.99\n- BUN (mg/dL) Mean: 13.9\n- BUN (mg/dL) Median: 15.8\n- WBC (K) Mean: 8.0\n- WBC (K) Median: 7.5\n- Platelets (K) Mean: 232\n- Platelets (K) Median: 213\n\n### Adverse Events\n- AE ID: AE-0111, Description: insomnia, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0112, Description: fatigue, Grade: 1, Relatedness: unlikely related, Resolved: true, Subject Group: statin\n- AE ID: AE-0113, Description: upper respiratory infection, Grade: 1, Relatedness: not related, Resolved: true, Subject Group: statin\n- AE ID: AE-0114, Description: hepatocellular injury, Grade: 3, Relatedness: probably related, Resolved: true, Subject Group: statin\n\n### Concomitant Meds\n- Statin Count: 38\n- ACE Inhibitor Count: 30\n- Metformin Count: 23\n- PPI Count: 19\n- NSAID Count: 12\n- Other Count: 32\n\n### Protocol Deviations\n- PD ID: PD-056, Description: Incorrect lab panel order, repeated, Severity: minor, Site: site_10\n- PD ID: PD-057, Description: IP temperature excursion during shipment, 2h out of range, Severity: moderate, Site: site_06\n- PD ID: PD-058, Description: Blood draw outside protocol-specified fasting window, Severity: minor, Site: site_08\n\n### Investigator Notes\n- Query resolution rate at 94%\n- Central lab results received within 48h turnaround\n- IRB approved protocol amendment v4.0; all sites notified\n- Statin co-administered subjects transitioning off statins per amended protocol\n\n### Events\n- IVRS system update deployed, randomization unaffected\n- Site 10 pharmacy temperature log reviewed: compliant\n- Protocol amendment v4.0 approved; site distribution initiated\n\n### Notes\n- Week 27: Protocol amendment v4.0 under IRB review/approval. Statin subjects transitioning.",
  "metadata": {
    "episode_id": "clinical_signal_03_ep_027",
    "scope_id": "clinical_signal_03",
    "timestamp": "2024-09-02T10:00:00",
    "phase": "root_cause",
    "signal_density": "high",
    "episode_type": "signal",
    "layer_name": "signal_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "724335e48952198659b608a79f591f6985cc457d1b0726c271a193e4d218a284",
      "components": {
        "transform": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
        "inputs": "a94b84fbaca9bd62"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "f5403588af46952374060f29447e5a7639e5b66fc9aef1799b08473882c4bcbc",
      "components": {
        "transform_id": "cb4ddfa83a38701b",
        "source": "42e76241d396a578",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}